Alvotech overview and recent share performance context Alvotech (NasdaqGM:ALVO) develops and manufactures biosimilar medicines across autoimmune, eye, bone disorder, and cancer indications, and its ...

After a volatile 2025, investors are searching for clues for what may lie ahead in 2026. At the start of each year, two popular market theories — the January effect and the January barometer — seem to ...

National banks identified as CX leaders delivered a cumulative total stock return 2.4 times greater than CX laggards over a ...

Amazon.com (AMZN) shares have decreased by 13.8% over the last 21 trading sessions. This recent decline is indicative of renewed worries surrounding significant AI investments and their effects on ...

Legrand focuses on electrical and digital building infrastructure. Read more on what investors should know about this French ...

・Nvidia Director Mark Stevens sold nearly $40 million worth of shares of the company last week; he sold over $100 million worth of shares in December. ・Insiders have largely sold stock over the past ...

Palantir has been delivering strong revenue growth and stock performance in recent years. The company offers customers an easy way to apply AI to their needs. So, investors have gotten used to solid ...

This company soared into the spotlight with its first product a few years ago. But in recent years, the company's earnings and stock price declined. 10 stocks we like better than Moderna › The first ...

CAAT Pension Plan earned 8.4% last year as buoyant stock performance outweighed soft returns in the fund’s private market ...

Trades linked to Khanna have delivered returns that surpass those of other lawmakers.

Palantir helps its customers immediately apply AI to their needs -- and that’s resulted in explosive growth. The company’s customer count and contract value are both on the rise. This AI focus has ...